Identification
- Summary
Difluprednate is a topical corticosteroid used for the symptomatic treatment of inflammation and pain associated with ocular surgery.
- Brand Names
- Durezol
- Generic Name
- Difluprednate
- DrugBank Accession Number
- DB06781
- Background
Difluprednate is a topical corticosteroid indicated for the treatment of infammation and pain associated with ocular surgery. It is a butyrate ester of 6(α), 9(α)-difluoro prednisolone acetate. Difluprednate is abbreviated DFBA, or difluoroprednisolone butyrate acetate. It is indicated for treatment of endogenous anterior uveiti.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Difluprednate (DB06781)
- Weight
- Average: 508.5515
Monoisotopic: 508.227259852 - Chemical Formula
- C27H34F2O7
- Synonyms
- DFBA
- Difluoroprednisolone butyrate acetate
- Difluprednate
- External IDs
- W 6309
- W-6309
Pharmacology
- Indication
For the treatment of inflammation and pain associated with ocular surgery.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Anterior uveitis •••••••••••• •••••••••• Treatment of Endogenous anterior uveitis •••••••••••• ••••••••• •••••••• Treatment of Eye pain •••••••••••• ••• ••••••• ••••••••• •••••••• Treatment of Eye inflammation •••••••••••• ••• ••••••• ••••••••• •••••••• Treatment of Pain of the eye •••••••••••• •••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Difluprednate is a corticosteroid used as an anti-inflammatory steroidal drug used primarily in ocular surgery.
- Mechanism of action
Corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins (lipocortins). It is postulated that these proteins control the biosynthesis of potent mediators of infammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
Target Actions Organism AGlucocorticoid receptor agonistHumans - Absorption
Difluprednate penetrates the corneal epithelium rapidly and effectively. Low systemic absorption.
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
Difluprednate is rapidly deacetylated in the aqueous humor to difluoroprednisolone butyrate (DFB), the drug’s active metabolite. Endogenous tissue esterases then metabolize DFB to the inert metabolite hydroxyfluoroprednisolone butyrate (HFB), which limits systemic exposure to the active compound.
Hover over products below to view reaction partners
- Route of elimination
78.5% of radioactivity was excreted aftert 24 hours, and 99.5% by 7 days after a single dose of labeled difluprednate instilled in the right eyes of pigmented rabbits.
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Preclinical pharmacokinetic and toxicity studies have established that difluprednate ophthalmic emulsion 0.05% given 4 times a day is not toxic to the eye.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbametapir The serum concentration of Difluprednate can be increased when it is combined with Abametapir. Acarbose The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Acarbose. Acetohexamide The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Acetohexamide. Acetyldigitoxin The risk or severity of adverse effects can be increased when Difluprednate is combined with Acetyldigitoxin. Albiglutide The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Albiglutide. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Durezol Emulsion 0.05 % w/v Ophthalmic Novartis 2014-02-19 Not applicable Canada 
Durezol Emulsion 0.5 mg/1mL Ophthalmic Sirion Therapeutics, Inc. 2008-09-01 2010-06-24 US 
Durezol Emulsion 0.5 mg/1mL Ophthalmic ALCON LABORATORIES, INC. 2011-01-25 2023-08-31 US Durezol Emulsion 0.5 mg/1mL Ophthalmic Novartis Pharmaceuticals Corporation 2011-01-25 Not applicable US Durezol Emulsion 0.5 mg/1mL Ophthalmic Physicians Total Care, Inc. 2011-08-29 Not applicable US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Difluprednate Emulsion 0.5 mg/1mL Ophthalmic Exelan Pharmaceuticals, Inc. 2021-12-10 Not applicable US Difluprednate Emulsion 0.5 mg/1mL Ophthalmic Cipla USA Inc. 2021-08-09 Not applicable US Difluprednate Emulsion 0.5 mg/1mL Ophthalmic Amneal Pharmaceuticals NY LLC 2021-11-18 Not applicable US Difluprednate Ophthalmic Emulsion 0.5 mg/1mL Ophthalmic Sandoz Inc 2013-05-15 Not applicable US Difluprednate Ophthalmic Emulsion Emulsion 0.5 mg/1mL Ophthalmic Dr. Reddy's Laboratories Inc. 2022-12-25 Not applicable US
Categories
- ATC Codes
- D07AC19 — Difluprednate
- Drug Categories
- Adrenal Cortex Hormones
- Corticosteroids
- Corticosteroids, Dermatological Preparations
- Corticosteroids, Potent (Group III)
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 Substrates
- Dermatologicals
- Fused-Ring Compounds
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Immunosuppressive Agents
- Pregnadienes
- Pregnadienetriols
- Pregnanes
- Steroids
- Steroids, Fluorinated
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Pregnane steroids
- Direct Parent
- Gluco/mineralocorticoids, progestogins and derivatives
- Alternative Parents
- Steroid esters / 20-oxosteroids / 11-beta-hydroxysteroids / 3-oxo delta-1,4-steroids / Halogenated steroids / Delta-1,4-steroids / Alpha-acyloxy ketones / Dicarboxylic acids and derivatives / Cyclic ketones / Cyclic alcohols and derivatives show 7 more
- Substituents
- 11-beta-hydroxysteroid / 11-hydroxysteroid / 20-oxosteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / 6-halo-steroid / 9-halo-steroid / Alcohol / Aliphatic homopolycyclic compound / Alkyl fluoride show 24 more
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- butyrate ester, corticosteroid hormone (CHEBI:31485)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- S8A06QG2QE
- CAS number
- 23674-86-4
- InChI Key
- WYQPLTPSGFELIB-JTQPXKBDSA-N
- InChI
- InChI=1S/C27H34F2O7/c1-5-6-23(34)36-26(22(33)14-35-15(2)30)10-8-17-18-12-20(28)19-11-16(31)7-9-24(19,3)27(18,29)21(32)13-25(17,26)4/h7,9,11,17-18,20-21,32H,5-6,8,10,12-14H2,1-4H3/t17-,18-,20-,21-,24-,25-,26-,27-/m0/s1
- IUPAC Name
- (1R,3aS,3bS,5S,9aS,9bR,10S,11aS)-1-[2-(acetyloxy)acetyl]-5,9b-difluoro-10-hydroxy-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl butanoate
- SMILES
- [H][C@@]12CC[C@](OC(=O)CCC)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
References
- Synthesis Reference
Ercoli, A. and Gardi, R.; U.S. Patent 3,780,177; December 18,1973; assigned to Warner-Lambert Co.
- General References
- Korenfeld MS, Silverstein SM, Cooke DL, Vogel R, Crockett RS: Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. J Cataract Refract Surg. 2009 Jan;35(1):26-34. doi: 10.1016/j.jcrs.2008.09.024. [Article]
- Jamal KN, Callanan DG: The role of difluprednate ophthalmic emulsion in clinical practice. Clin Ophthalmol. 2009;3:381-90. Epub 2009 Jun 29. [Article]
- Morton KD, Van de Kar LD, Brownfield MS, Bethea CL: Neuronal cell bodies in the hypothalamic paraventricular nucleus mediate stress-induced renin and corticosterone secretion. Neuroendocrinology. 1989 Jul;50(1):73-80. [Article]
- External Links
- Human Metabolome Database
- HMDB0061149
- KEGG Drug
- D01266
- KEGG Compound
- C12695
- PubChem Compound
- 443936
- PubChem Substance
- 99443292
- ChemSpider
- 391990
- 23043
- ChEBI
- 31485
- ChEMBL
- CHEMBL1201749
- ZINC
- ZINC000004212945
- PharmGKB
- PA165958405
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Difluprednate
- FDA label
- Download (149 KB)
- MSDS
- Download (129 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Cataracts 1 4 Completed Treatment Cataracts / Corneal Edema / Retinal Structural Change, Deposit and Degeneration / Visual Acuity Reduced Transiently 1 4 Recruiting Treatment Anterior Uveitis (AU) 1 4 Terminated Treatment Cataracts 1 4 Terminated Treatment Macular Edema / Uveitis 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Emulsion Ophthalmic 0.50 mg Ointment 20 g Emulsion Ophthalmic 0.05 % w/v Emulsion Ophthalmic 0.5 mg/1mL Solution Ophthalmic 0.5 mg Solution Ophthalmic; Topical 0.5 mg Ointment 0.05 % - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US6114319 Yes 2000-09-05 2019-11-18 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 191-194 Ercoli, A. and Gardi, R.; U.S. Patent 3,780,177; December 18,1973; assigned to Warner-Lambert Co. - Predicted Properties
Property Value Source Water Solubility 0.0097 mg/mL ALOGPS logP 3.28 ALOGPS logP 3 Chemaxon logS -4.7 ALOGPS pKa (Strongest Acidic) 13.6 Chemaxon pKa (Strongest Basic) -3.4 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 106.97 Å2 Chemaxon Rotatable Bond Count 8 Chemaxon Refractivity 125.38 m3·mol-1 Chemaxon Polarizability 51.45 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9904 Blood Brain Barrier + 0.9908 Caco-2 permeable + 0.6127 P-glycoprotein substrate Substrate 0.7679 P-glycoprotein inhibitor I Inhibitor 0.6413 P-glycoprotein inhibitor II Non-inhibitor 0.789 Renal organic cation transporter Non-inhibitor 0.8044 CYP450 2C9 substrate Non-substrate 0.8882 CYP450 2D6 substrate Non-substrate 0.9152 CYP450 3A4 substrate Substrate 0.7641 CYP450 1A2 substrate Non-inhibitor 0.9138 CYP450 2C9 inhibitor Non-inhibitor 0.911 CYP450 2D6 inhibitor Non-inhibitor 0.8162 CYP450 2C19 inhibitor Non-inhibitor 0.94 CYP450 3A4 inhibitor Non-inhibitor 0.7263 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9014 Ames test Non AMES toxic 0.9326 Carcinogenicity Non-carcinogens 0.9242 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 2.1368 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9677 hERG inhibition (predictor II) Non-inhibitor 0.5493
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 229.7903609 predictedDarkChem Lite v0.1.0 [M-H]- 227.3684609 predictedDarkChem Lite v0.1.0 [M-H]- 215.4412 predictedDeepCCS 1.0 (2019) [M-H]- 229.7903609 predictedDarkChem Lite v0.1.0 [M-H]- 227.3684609 predictedDarkChem Lite v0.1.0 [M-H]- 215.4412 predictedDeepCCS 1.0 (2019) [M+H]+ 227.8008609 predictedDarkChem Lite v0.1.0 [M+H]+ 226.4771609 predictedDarkChem Lite v0.1.0 [M+H]+ 217.31184 predictedDeepCCS 1.0 (2019) [M+H]+ 227.8008609 predictedDarkChem Lite v0.1.0 [M+H]+ 226.4771609 predictedDarkChem Lite v0.1.0 [M+H]+ 217.31184 predictedDeepCCS 1.0 (2019) [M+Na]+ 229.3034609 predictedDarkChem Lite v0.1.0 [M+Na]+ 227.5840609 predictedDarkChem Lite v0.1.0 [M+Na]+ 223.39073 predictedDeepCCS 1.0 (2019) [M+Na]+ 229.3034609 predictedDarkChem Lite v0.1.0 [M+Na]+ 227.5840609 predictedDarkChem Lite v0.1.0 [M+Na]+ 223.39073 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Zinc ion binding
- Specific Function
- Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
- Gene Name
- NR3C1
- Uniprot ID
- P04150
- Uniprot Name
- Glucocorticoid receptor
- Molecular Weight
- 85658.57 Da
References
- Jamal KN, Callanan DG: The role of difluprednate ophthalmic emulsion in clinical practice. Clin Ophthalmol. 2009;3:381-90. Epub 2009 Jun 29. [Article]
- Tajika T, Takahashi H, Sakai Y, Fujii H, Isowaki A, Sakaki H: Metabolic profiles of difluprednate in rabbit ocular tissues after instillation of difluprednate ophthalmic emulsion. Xenobiotica. 2010 Aug;40(8):569-77. doi: 10.3109/00498254.2010.490308. [Article]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Cerny MA: Prevalence of Non-Cytochrome P450-Mediated Metabolism in Food and Drug Administration-Approved Oral and Intravenous Drugs: 2006-2015. Drug Metab Dispos. 2016 Aug;44(8):1246-52. doi: 10.1124/dmd.116.070763. Epub 2016 Apr 15. [Article]
Drug created at September 14, 2010 16:21 / Updated at April 18, 2024 09:15